By Fineline Cube 
Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and Guangzhou Baiyunshan Xihe Health Medicine Co., Ltd. announced the signing of a strategic cooperation agreement. The collaboration will focus on the co‑development of novel radiopharmaceuticals and radioactive diagnostic products.
Deal Overview
| Item | Detail |
|---|---|
| Companies | Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. / Guangzhou Baiyunshan Xihe Health Medicine Co., Ltd. |
| Agreement Type | Strategic cooperation agreement |
| Focus Areas | Novel radiopharmaceuticals and radioactive diagnostic products |
| Announcement Date | 3 Jul 2026 |
| Target Application | Precision diagnosis and treatment in oncology |
Scope of the Collaboration
- Complementary Strengths: The partnership aims to integrate Sanyou’s core strength in AI‑driven innovative drug molecular discovery with Baiyunshan Xihe’s capabilities across the full industrial chain of nuclear medicine.
- End‑to‑End Pipeline: Together, the two parties will establish a complete innovation pipeline from targeted molecular discovery to clinical translation of radiopharmaceuticals.
- Oncology Focus: The collaboration targets groundbreaking solutions for precision diagnosis and treatment in oncology, where radiopharmaceuticals are emerging as one of the fastest‑growing therapeutic categories.
Technology & Platform Profile
- AI‑Driven Discovery: Sanyou applies artificial intelligence to innovative molecular discovery, aiming to identify novel targeting ligands for radiopharmaceutical development — a process traditionally slow and costly.
- Nuclear Medicine Value Chain: Baiyunshan Xihe brings resources spanning the full industrial chain of nuclear medicine, from isotope supply and manufacturing to clinical and commercial infrastructure.
- Combination Logic: Pairing AI‑accelerated target and ligand discovery with an integrated nuclear medicine platform is designed to shorten the path from molecular identification to clinical‑stage radiopharmaceutical candidates.
Market Impact & Outlook
- Radiopharmaceutical Momentum: Radioligand therapy and nuclear diagnostics have become one of the hottest segments in global oncology, driven by the clinical success of PSMA‑ and SSTR‑targeted agents.
- China’s Nuclear Medicine Push: China is accelerating investment in isotope supply chains and radiopharmaceutical innovation, positioning domestic players to compete in a market historically dominated by multinationals.
- AI + Radiopharma Convergence: The deal reflects a broader industry trend of combining AI‑driven discovery with nuclear medicine to expand the pipeline of targeted radioactive drugs.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding pipeline development and collaboration intentions. Actual results may differ due to risks including regulatory approvals, clinical outcomes, and definitive project agreements.-Fineline Info & Tech